Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises

Author(s): D. Cortinovis, V. Monica, F Pietrantonio, G.L. Ceresoli, C.M. La Spina and L. Wannesson

Volume 20, Issue 24, 2014

Page: [3982 - 3990] Pages: 9

DOI: 10.2174/13816128113196660755

Price: $65

Abstract

A biological characterization of tumor tissue is mandatory in NSCLC patients to identify cases at high risk of recurrence and to drive current targeted therapies such as EGFR and ALK inhibitors. In addition, promising results have been reported on the utility of molecular parameters for the prediction of the efficacy of systemic cytotoxic therapy. MicroRNAs (miRNAs) are small single stranded non-coding RNA molecules, which regulate gene expression at the posttranscriptional level. Growing evidence suggests that miRNAs are expressed aberrantly in many human cancers and that they play a significant role in carcinogenesis and cancer progression. There is increasing evidence that miRNA profiling may become an accurate way to differentiate tumor subtypes, determine prognosis and response to therapy. This review aims to summarize the current literature on this rapidly evolving field.

Keywords: miRNA, prognostic, predictive, therapy, NSCLC.

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy